NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
Am-Pharma announces updated clinical development strategy<
26 Sep 2023

Am-Pharma announces updated clinical development strategy

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage
Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas<
14 Sep 2023

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors
Xeltis appoints Luciën van Os as Chief Operating Officer<
12 Sep 2023

Xeltis appoints Luciën van Os as Chief Operating Officer

Luciën joins Xeltis with more than 20 years of experience in the life sciences sector
Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension<
10 Sep 2023

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension
Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions<
10 Sep 2023

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial<
30 Aug 2023

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

Positive recommendation received from Data Safety Monitoring Board (DSMB) to dose second cohort

SparingVision Named a ‘Fierce 15’ Company by Fierce Biotech<
28 Aug 2023

SparingVision Named a ‘Fierce 15’ Company by Fierce Biotech

We are honored to be recognized among the prestigious Fierce 15 as a leading innovator in the biotech sector
Lava Therapeutics provides business update and reports second quarter 2023 financial results<
22 Aug 2023

Lava Therapeutics provides business update and reports second quarter 2023 financial results

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing<
14 Aug 2023

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing

Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights<
09 Aug 2023

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Strengthened Clinical and Regulatory Leadership Team with Key Appointments

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка